Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol

Vita Manzoli,Chiara Villa,Allison L Bayer,Laura C Morales,R Damaris Molano,Yvan Torrente,Camillo Ricordi,Jeffrey A Hubbell,Alice A Tomei,Allison L. Bayer,Laura C. Morales,R. Damaris Molano,Jeffrey A. Hubbell,Alice A. Tomei

DOI: https://doi.org/10.1111/ajt.14547

IF: 9.369

2017-12-02

American Journal of Transplantation

Abstract:Islet encapsulation may allow transplantation without immunosuppression, but thus far islets in large microcapsules transplanted in the peritoneal cavity have failed to reverse diabetes in humans. We showed that islet transplantation in confined well-vascularized sites like the epididymal fat pad (EFP) improved graft outcomes, but only conformal coated (CC) islets can be implanted in these sites in curative doses. Here, we showed that CC using polyethylene glycol (PEG) and alginate (ALG) was not immunoisolating because of its high permselectivity and strong allogeneic T cell responses. We refined the CC composition and explored PEG and islet-like extracellular matrix (Matrigel; MG) islet encapsulation (PEG MG) to improve capsule immunoisolation by decreasing its permselectivity and immunogenicity while allowing physiological islet function. Although the efficiency of diabetes reversal of allogeneic but not syngeneic CC islets was lower than that of naked islets, we showed that CC (PEG MG) islets from fully MHC-mismatched Balb/c mice supported long-term (>100 days) survival after transplantation into diabetic C57BL/6 recipients in the EFP site (750-1000 islet equivalents/mouse) in the absence of immunosuppression. Lack of immune cell penetration and T cell allogeneic priming was observed. These studies support the use of CC (PEG MG) for islet encapsulation and transplantation in clinically relevant sites without chronic immunosuppression.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to achieve successful islet transplantation at clinically relevant and highly vascularized sites without long - term immunosuppression in allogeneic islet transplantation by using polyethylene glycol (PEG) and a material similar to islet extracellular matrix (Matrigel, MG) for conformal coating (CC). Specifically, the research aims to:

1. **Improve the immunoisolation performance of islet coating materials**: Although traditional coating materials such as the combination of polyethylene glycol and alginate (PEG - ALG) can protect islets, their high permeability and strong allogeneic T - cell responses lead to poor immunoisolation effects, thus affecting the transplantation results. Therefore, researchers try to improve the composition of the coating materials to reduce their permeability and immunogenicity while maintaining the physiological functions of islets.

2. **Optimize the site of islet transplantation**: Traditional islet transplantation mostly selects the intraperitoneal (IP) as the transplantation site, but due to the large size of the capsules, the failure rate of transplantation is relatively high. Researchers explore the possibility of transplantation at smaller and more vascularized sites such as the epididymal fat pad (EFP). These sites can accommodate islet coatings with a smaller volume, thereby increasing the success rate of transplantation.

3. **Achieve long - term diabetes reversal**: Researchers hope to develop an islet transplantation method that can achieve long - term diabetes reversal without using immunosuppressants. By using the improved PEG - MG conformal coating technology, researchers conducted experiments in a mouse model with a completely mismatched major histocompatibility complex (MHC). The results showed that the transplanted islets could survive for a long time and maintain stable blood glucose levels, and no obvious immune cell infiltration or T - cell allogeneic activation was observed.

In summary, the main goal of this paper is to achieve islet transplantation without long - term immunosuppression by improving islet coating materials and their transplantation sites, thereby providing more extensive and effective treatment options for type 1 diabetes patients.